Mumbai |Seoul | Mexico City, July 18, 2024 – Global pharma major Lupin Limited (Lupin) today announced that it has signed a license and supply agreement with Huons Co. Ltd for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion,0.4mL Single-use Vial, in Mexico.

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome and healing corneal ulcers. Thanks to its unique nanoparticle technology, it can relieve symptoms faster by increasing the tear production in patients with suppressed tear formation due to keratoconjunctivitis sicca-related ocular inflammatory disease.

“We are delighted to partner with Huons to introduce cyclosporine ophthalmic nanoemulsionin Mexico and offer a novel technology that provides significant benefits to our patients suffering from Dry eye. With this addition to our Ophthalmology portfolio, we continue to strengthen our commitment to provide better healthcare and Eyecare solutions to our patients, improving patient quality of life and vision,” said Dr. Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.

Mr. Yohun Aum, Senior Director – Head of Global Business Division, Huons said, “Introducing our Cyclosporine Ophthalmic Nanoemulsion in Mexico is a significant milestone for Huons. We look forward to strengthening our partnership by supplying high quality products for Mexico.”

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector. Please visit www.lupin.com for more information.

Follow us on:
Twitter: https://twitter.com/LupinGlobal
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: https://www.facebook.com/LupinWorld/

About Huons
Huons, a subsidiary of Huons Global, is the leading pharmaceutical company in Korea with a history of 60 years of manufacturing and supplying various prescription drugs – from eye drops, injections to oral solids. It is not only expanding its business in the pharmaceutical area but also in bio-pharmaceuticals, medical devices and nutraceuticals.

Huons is especially strong in preparation of sterile formulations that require complex management, such as injections and eye drops. Huons is exporting it’s US FDA approved anesthetics – Lidocaine injections and Bupivacaine injections – to the US and is actively expanding to other parts of the world.

For further information or queries please contact –

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com